

24 September 2019, Ankara HiltonSA, Turkey

2nd Turkish Interactive Workshop on **REGULATORY ASSESSMENT OF BIOSIMILARS**



Professor Tore Kristian Kvien, MD, PhD, Norway

- Professor of Rheumatology, University of Oslo, Norway
- Head of the Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway








24 September 2019, Ankara HiltonSA, Turkey

2nd Turkish Interactive Workshop on **REGULATORY ASSESSMENT OF BIOSIMILARS**




An update on biosimilars and switching experience – the clinical perspective

Professor Tore Kristian Kvien, MD, PhD 24 September 2019





An update on biosimilars and switching experience – the clinical perspective



Tore K Kvien

Dept of Rheumatology Diakonhjemmet Hospital Oslo, Norway

Tore K Kvien – disclosures

	Honorarium		Institutional support NOR-DMARD		
	Presentation	Advice	Previous	Current	
AbbVie	X	Х	Х		
BMS	X	Х	Х	Х	
MSD	X	Х	X		
Pfizer/Wyeth	X	Х	Х		
Roche	X	Х	Х		
UCB	X	Х	Х		
Hospira/Pfizer	X	Х			
Epirus		Х			
Orion	X	Х			
Merck Serono		Х			
Mundipharma	X				
Celltrion	X	Х			
Sandoz	X				
Samsung	X				
Biogen	X	Х			
Amgen	Х				

What is a biosimilar?

- A biosimilar is a legitimate copy of a biopharmaceutical, which no longer is protected by patent, that has:
 - -Undergone rigorous analytical and clinical assessment, in comparison to its reference product, and
 - Been approved by a regulatory agency according to a specific pathway for biosimilar evaluation

Intended copies/Me-too biologicals

... While these products apparently meet local regulatory requirements, they should not be considered biosimilars, but rather, 'intended copies'. Physicians must be aware of the distinction between these and 'true' biosimilars that meet EMA/FDA standards, as well as the differences between biosimilars and other 'biological copies'.

Intended copies' of innovator biologics currently in use for treatment of rheumatoid arthritis (not subjected to current European Medicines Agency/ Food and Drug Administration Standards for bio similarity at the time of approval)¹

Reference product	Manufacturer	'Intended copy'	Marketed locations
Rituximab	Dr Reddy's Iaboratories (India)	Reditux	Bolivia, Chile, India and Peru
Rituximab	Probiomed (Mexico)	Kikuzubm	Bolivia, Chile, Mexico and Peru
Etanercept	Shanghai CP Guojian	Etanar	Colombia
Etanercept	 Pharmaceutical Co (China) 	Yisaipu	China

1. Dörner T et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013;72:322-8

Why Biosimilars?

- Similar to the originator product
 - -Not better
 - -Not worse


-But less expensive!

Could improve accessibility to good therapies for more people with RMDs


EXTENDED REPORT

Inequities in access to biologic and synthetic DMARDs across 46 European countries

Polina Putrik,¹ Sofia Ramiro,² Tore K Kvien,³ Tuulikki Sokka,⁴ Milena Pavlova,⁵ Till Uhlig,⁶ Annelies Boonen,⁷ Working Group 'Equity in access to treatment of rheumatoid arthritis in Europe'




Inequities in Access to Biologic and Synthetic DMARDs Across 46 European Countries





Putrik P, et al. Ann Rheum Dis 2014;73:198-206.

Generics and Biosimilars



Two Main Questions


 Prescription of biosimilar when to start new therapy or to change therapy for medical reasons?

-Not controversial (?)

Comparison of Regulatory Requirements

• The aim of a biosimilar development program is to establish *"biosimilarity"* based upon totality of evidence.

Biosimilar mAb Development



New Drug Development

- 1. Guideline on similar biological medicinal products. European Medicines Agency 23rd October 2014.
- 2. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf (Accessed October 2016).

PLANETRA


 Standard design and inclusion criteria for phase 3 trial in pts being IA responders to MTX

• Primary endpoint ACR20 week 30

• Equivalence of efficacy if the 95% CI for treatment difference was within + 15%

Phase 3 Therapeutic Equivalence Trial in RA: Study Schematic

Randomised double-blind study in patients with RA




^{*}Doses at weeks 0, 2 and 6 by 2-hr IV infusion.

**Doses every 8 weeks up to 54 weeks by 2-hr IV infusion.

CT-P13 Study in RA: ACR20 Response

ACR response at Weeks 14, 30 and 54 Estimate of treatment difference (95% CI)



ARD Online First, published on September 22, 2015 as 10.1136/annrheumdis-2015-207588 Clinical and epidemiological research



OPEN ACCESS


EXTENDED REPORT

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

Paul Emery,¹ Jiří Vencovský,² Anna Sylwestrzak,³ Piotr Leszczyński,⁴ Wieslawa Porawska,⁵ Asta Baranauskaite,⁶ Vira Tseluyko,⁷ Vyacheslav M Zhdan,⁸ Barbara Stasiuk,⁹ Roma Milasiene,¹⁰ Aaron Alejandro Barrera Rodriguez,¹¹ Soo Yeon Cheong,¹² Jeehoon Ghil¹²

To cite: Emery P, Vencovský J, Sylwestrzak A, et al. Ann Rheum Dis 2017;76:51–57.


ACR20 Response Rate at Week 24 Equivalent between SB4 and ETN




ACR20, American College of Rheumatology 20% response; ETN, etanercept.

Emery P, et al. Ann Rheum Dis. Jul 6. pii: annrheumdis-2015-207588.

ACR50, ACR70 Response Rates at Week 24 Comparable between SB4 and ETN




*One patient from the SB4 group was excluded from the FAS due to missing efficacy data at



etanercept; FAS: full analysis set; NRI: non-responder imputation; PPS, per-protocol

Emery P, et al. Ann Rheum Dis. Jul 6. pii: annrheumdis-2015-207588.

Multicenter, randomized, double-blind, comparator-controlled Phase III confirmatory study with four study periods



ADA, proposed biosimilar adalimumab; refADA, reference adalimumab

Biopharmaceuticals/Global Medical Affairs



	Patients	Patients with PASI 75 response at week 16	Adjusted response rate, % ± SE	Adjusted response rate difference, $\% \pm SE$	95% CI (equivalence margin of \pm 18%)
Analysis on per	protocol set				
GP2017	197	132	66.8 ± 3.33	1.8 ± 4.75	-7.46 to 11.15
Ref-ADMB	196	127	65.0 ± 3.38		
Supportive analy	sis on full analy	rsis set			
GP2017	231	134	58.1 ± 3.23	2.2 ± 4.56	-6.79 to 11.10
Ref-ADMB	234	131	55.9 ± 3.23		
		d measures analysis on perce	ntage change from baselin	e in PASI up to week 16 (key	secondary end point)
		d measures analysis on percer Patients with evaluable data	ntage change from baselin Least squares means, % ± SE	e in PASI up to week 16 (key Least squares means difference, % ± SE	95% CI (equivalenc
Mixed-effects m	odel for repeate Patients	Patients with	Least squares	Least squares means	secondary end point) 95% CI (equivalenc margin of ± 15%)
Mixed-effects m	odel for repeate Patients	Patients with	Least squares	Least squares means	95% CI (equivalenc
Mixed-effects m Analysis on per	odel for repeate Patients protocol set	Patients with evaluable data	Least squares means, % ± SE	Least squares means difference, % ± SE	95% CI (equivalenc margin of ± 15%)
Mixed-effects m Analysis on per GP2017 Ref-ADMB	odel for repeate Patients protocol set 197 196	Patients with evaluable data 191 192	Least squares means, % \pm SE -60.7 \pm 1.54	Least squares means difference, % ± SE	95% CI (equivalenc margin of ± 15%)
Mixed-effects m Analysis on per GP2017	odel for repeate Patients protocol set 197 196	Patients with evaluable data 191 192	Least squares means, % \pm SE -60.7 \pm 1.54	Least squares means difference, % ± SE	95% CI (equivalenc margin of ± 15%)

PASI, Psoriasis Area and Severity Index; SE, standard error; CI, confidence interval; GP2017, Sandoz proposed biosimilar adalimumab; ref-ADMB, reference adalimumab.

Extrapolation of indications

 The stringency of the regulatory pathway for acceptance ("the comparability exercise") also leads to acceptance of the concept of extrapolation.

• Some scepticism originally – but now generally accepted after 5 years experience and several studies with real life data also in IBD.

Types of Treatments for RA: Nomenclature

Disease Modifying Antirheumatic Drugs (DMARDs)

Synthetic DMARDs (sDMARDs)		Biological DMARDs (bDMARDs)		
Conventional synthetic (csDMARDs	Targeted synthetic (tsDMARDs)	Biological originator (boDMARDs)	Biosimilar (bsDMARDs)	
MTX, SSZ, LEF	Tofacitinib Baricitinib			

Smolen JS, et al. Ann Rheum Dis 2014 Jan;73(1):3-5.

Two main questions

 Prescription of biosimilar when to start new therapy or to change therapy for medical reasons?

- Not controversial (?)

 Can patients on stable treatment with an originator drug be switched to a cheaper biosimilar of this drug?

More controversial (concerning efficacy, safety and immunogenicity)

Evidence to support switching from reference product to biosimilar for non-medical reasons

- Extension of phase 3 RCTs
- Switching within RCTs
- Real life data
- Randomizing patients on stable long-term treatment

Clinical and epidemiological research



EXTENDED REPORT

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

Won Park,¹ Dae Hyun Yoo,² Pedro Miranda,³ Marek Brzosko,⁴ Piotr Wiland,⁵ Sergio Gutierrez-Ureña,⁶ Helena Mikazane,⁷ Yeon-Ah Lee,⁸ Svitlana Smiyan,⁹ Mie-Jin Lim,¹ Vladimir Kadinov,¹⁰ Carlos Abud-Mendoza,¹¹ HoUng Kim,¹² Sang Joon Lee,¹² YunJu Bae,¹² SuYeon Kim,¹² Jürgen Braun¹³


EXTENDED REPORT




Clinical and epidemiological research

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

Dae Hyun Yoo, ¹ Nenad Prodanovic, ² Janusz Jaworski, ³ Pedro Miranda, ⁴ Edgar Ramiterre, ⁵ Allan Lanzon, ⁶ Asta Baranauskaite, ⁷ Piotr Wiland, ⁸ Carlos Abud-Mendoza, ⁹ Boycho Oparanov, ¹⁰ Svitlana Smiyan, ¹¹ HoUng Kim, ¹² Sang Joon Lee, ¹² SuYeon Kim, ¹² Won Park¹³




Study design – EGALITY study



ETN, reference etanercept; TP, treatment period; Wk, week Griffiths CE et al. Br J Dermatol. 2016 Oct 27. doi: 10.1111/bjd.15152. [Epub ahead of print]


Biosimilar Switch Study

GP2015 in PsO^a



^a Griffiths, C.E.M., Thaçi, D., Gerdes, S., Arenberger, P., Pulka, G., Kingo, K., Weglowska, J., the EGALITY study group, Hattebuhr, N., Poetzl, J., Woehling, H., Wuerth, G. and Afonso, M. (2017), The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol, 176: 928–938. doi:10.1111/bjd.15152

Multicenter, randomized, double-blind, comparator-controlled Phase III confirmatory study with four study periods






ADA, proposed biosimilar adalimumab; refADA, reference adalimumab

Efficacy was similar and sustained in patients Week 51 continuously treated with ADA or refADA, or switched between ADA and refADA

PASI response rates over time



ADA, proposed biosimilar adalimumab; PASI, Psoriasis Area and Severity Index; refADA, reference adalimumab




Biopharmaceuticals/Global Medical Affairs

Non-Medical Switches

- Switch from originator bDMARD to biosimilar for non medical reasons
- Non-medical switch, DK: May 2015: originator infliximab > biosimilar CT-P13 April 2016: originator etanercept > biosimilar SB4
- All Danish patients with inflammatory diseases (rheumatology, dermatology, gastroenterology)

Date of infliximab switch, DANBIO



CONCISE REPORT

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Bente Glintborg,^{1,2} Inge Juul Sørensen,^{3,4} Anne Gitte Loft,⁵ Hanne Lindegaard,⁶ Asta Linauskas,⁷ Oliver Hendricks,⁸ Inger Marie Jensen Hansen,⁹ Dorte Vendelbo Jensen,^{2,3} Natalia Manilo,¹⁰ Jakob Espesen,¹¹ Mette Klarlund,¹² Jolanta Grydehøj,¹³ Sabine Sparre Dieperink,³ Salome Kristensen,¹⁴ Jimmi Sloth Olsen,¹⁵ Henrik Nordin,¹⁶ Stavros Chrysidis,¹⁷ Dorte Dalsgaard Pedersen,¹⁸ Michael Veedfald Sørensen,¹⁹ Lis Smedegaard Andersen,²⁰ Kathrine Lederballe Grøn,³ Niels Steen Krogh,²¹ Lars Pedersen,²² Merete Lund Hetland, ^{1,4}On behalf of all departments of rheumatology in Denmark

> **To cite:** Glintborg B, Sørensen IJ, Loft AG, *et al. Ann Rheum Dis* Published Online First: [*please include* Day Month Year]. doi:10.1136/ annrheumdis-2016-210742

Disease activity and flares


	Disease activity		Changes	over time	P*	
	3 months pre-switch	Switch	3 months post-switch	∆pre-switch	∆post-switch	
RA, n=403						
Patients with available data, n	319	310	309	276	265	-
DAS28	2.2	2.2	2.2	0.1	0.0	0.8
HAQ (0-3)	0.6	0.6	0.6	0.0	0.1	0.3
CRP, mg/l (<10mg/L)	4	4.5	5	0	0	0.4
Patient's global score, mm	26	25	26	0.0	0.0	0.5
PsA, n=120						
Patients with available data, n	94	92	94	78	81	-
DAS28	2.5	2.3	2.4	0.0	0.1	0.10
HAQ (0-3)	0.5	0.6	0.5	0.0	0.0	0.5
CRP, mg/l (<10mg/L)	4	4	3	0	0	0.046
Patient's global score, mm	32	34	35	-3	0	0.01
AxSpA, n=279						
Patients with available data, n	202	199	204	160	169	-
BASDAI, mm	23	24	25	0	0	0.3
CRP, mg/l	3	4	4	0	0	0.2
Patient's global score, mm	26	31	27	1	-1	0.7
ASDAS	1.8	2.0	2.0	0.0	0.0	0.8
Flare rates pre-switch vs. post-s	witch					
RA and PsA (∆DAS28≥0.6), %				22	22	
RA and PsA (∆DAS28≥1.2), %				10	10	
AxSpA (ΔASDAS>1.1), %				3	4	

Numbers are medians unless otherwise stated

Glintborg B, Sørensen IJ, Loft AG, et al. Ann Rheum Dis, Online First May 8th 2017 doi:10.1136/annrheumdis-2016-210742

Retention of Treatment

1 year treatment retention was compared to that of a historic cohort of all patients in DANBIO receiving treatment with Remicade by January 1st 2014



Glintborg B, Sørensen IJ, Loft AG, et al. Ann Rheum Dis, Online First May 8th 2017 doi:10.1136/annrheumdis-2016-210742

EXTENDED REPORT

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

Bente Glintborg, ^{1,2} Anne Gitte Loft, ^{3,4} Emina Omerovic, ⁵ Oliver Hendricks, ⁶ Asta Linauskas, ⁷ Jakob Espesen, ⁸ Kamilla Danebod, ² Dorte Vendelbo Jensen, ² Henrik Nordin, ⁹ Emil Barner Dalgaard, ¹⁰ Stavros Chrysidis, ¹¹ Salome Kristensen, ¹² Johnny Lillelund Raun, ¹³ Hanne Lindegaard, ¹⁴ Natalia Manilo, ¹⁵ Susanne Højmark Jakobsen, ¹⁶ Inger Marie Jensen Hansen, ¹⁶ Dorte Dalsgaard Pedersen, ¹⁷ Inge Juul Sørensen, ^{18,19} Lis Smedegaard Andersen, ²⁰ Jolanta Grydehøj, ²¹ Frank Mehnert, ²² Niels Steen Krogh, ²³ Merete Lund Hetland ^{18,19}

> **To cite:** Glintborg B, Loft AG, Omerovic E, *et al*. *Ann Rheum Dis* Epub ahead of print: [*please include* Day Month Year]. doi:10.1136/ annrheumdis-2018-213474

	Disease activity Changes over time				
	3 months preswitch	Switch	3 months postswitch	∆Preswitch	∆Postswitch
RA, n=933					
Patients with available data, n (%)*	639 (68)	745 (80)	568 (61)	485 (52)	436 (47)
DAS28	1.9 (1.3 to 2.8)	2.1 (1.6 to 3.0)	2.1 (1.7 to 3.1)	0.0 (0.0 to 0.0)	0.0 (-0.4 to 0.5)
HAQ (0–3)	0.8 (0.3 to 1.3)	0.8 (0.3 to 1.3)	0.8 (0.3 to 1.3)	0 (–1 to 1)	0 (-1 to 1)
CRP, mg/L	3 (1 to 7)	3 (1 to 6)	3 (1 to 6)	0 (-2 to 1)	0 (-1 to 1)
PGS, mm	30 (14 to 57)	29 (13 to 55)	32 (12 to 62)	0 (–11 to 8)	1 (-8 to 11)
PsA, n=351					
Patients with available data, n (%)*	223 (64)	253 (72)	197 (56)	158 (45)	152 (43)
DAS28	1.8 (1.1 to 2.4)	2.0 (1.6 to 2.8)	2.1 (1.5 to 2.8)	0.0 (0.0 to 0.0)	0.1 (-0.4 to 0.5)
HAQ (0-3)	0.5 (0.1 to 1.0)	0.5 (0.0 to 1.0)	0.5 (0.1 to 1.0)	0.0 (-0.1 to 0.1)	0.0 (-0.1 to 0.1)
CRP, mg/L	2 (1 to 4)	2 (1 to 4)	2 (1 to 4)	0 (-2 to 1)	0 (–1 to 1)
PGS, mm	33 (13 to 58)	30 (12 to 54)	31 (12 to 58)	0 (–9 to 6)	0 (-7 to 10)
AxSpA, n=337					
Patients with available data, n (%)*	187 (55)	217 (64)	243 (72)	117 (35)	168 (50)
BASDAI, mm	33 (15 to 52)	27 (12 to 47)	31 (18 to 52)	0 (–8 to 6)	1 (-3 to 10)
CRP, mg/L	3 (1 to 6)	3 (1 to 5)	3 (1 to 5)	0 (–2 to 1)	0 (–1 to 1)
PGS, mm	32 (15 to 59)	30 (12 to 53)	34 (17 to 60)	-1 (-13 to 6)	3 (-5 to 14)
ASDAS	1.9 (1.3 to 2.8)	1.9 (1.2 to 2.6)	1.9 (1.3 to 2.7)	-0.1 (-0.4 to 0.3)	0.1 (-0.2 to 0.6)
3 months' flare rates preswitch vs postsw	/itch†				
RA (∆DAS28 ≥0.6), %				22	24
PsA (∆DAS28 ≥0.6), %				21	23
RA (∆DAS28 ≥1.2), %				8	13
PsA (∆DAS28 ≥1.2), %				8	11
AxSpA (∆ASDAS >1.1), %				4	5

Table 2 Disease activity 3 months prior to vs 3 months after the switch from ETA to SB4 stratified by indication

amony withurawais due to LOL			
	RA	PsA	AxSpA
Patient number, n	80	20	20
Characteristics at the start of SB4			
Female, n (%)	58 (73)	11 (55)	7 (35)
Age, years	59 (52 to 70)	45 (36 to 56)	43 (38 to 56)
Concomitant MTX, n (%)	39 (49)	7 (35)	1 (5)
Patients with available data, n*	64	17	18
In remission, %	61	82	19
PGS, mm*	27 (12 to 54)	25 (13 to 63)	23 (13 to 44)
DAS28	2.2 (1.6 to 3.2)	1.8 (1.4 to 2.2)	-
CRP, mg/L	3 (1 to 8)	1 (1 to 5)	3 (1 to 6)
Swollen joint count	0 (0 to 1)	0 (0 to 0)	-
ASDAS	-	-	1.7 (1.4 to 2.4)
PASS yes, %	81	82	88
Reason for SB4 withdrawal, n (%)			
AE	34 (42)	7 (35)	6 (30)
LOE	38 (48)	11 (55)	13 (65)
Other/several/not stated	8 (10)	2 (10)	1 (5)
Characteristics at the restart of ETA in patients who stopped due to L	.OE and back-switched, n=62		
Patient number, n	38	11	13
Swollen joint count	2 (0 to 5)	0 (0 to 2)	-
CRP, mg/L	3 (2 to 11)	3 (2 to 7)	4 (1 to 6)
PGS, mm	64 (50 to 76)	78 (18 to 90)	42 (35 to 63)
Delta valuest in patients who stopped due to LOE and back-switched	1		
Patients with available data, n†	31	8	11
Delta-swollen joint count	1 (0 to 4)	0 (0 to 0)	-
Delta-CRP, mg/L	0 (-1 to 5)	1 (0 to 2)	0 (0 to 4)
Delta-PGS, mm	30 (12 to 52)	15 (7 to 77)	25 (19 to 35)

 Table 5
 ETA-SB4-ETA back-switchers (n=120). Characteristics at the start of SB4, reasons for SB4 withdrawal and changes in disease activity among withdrawals due to LOE

.

The Nor-Switch Study

A randomized, double-blind, parallel-group study to evaluate the safety and efficacy of switching from innovator infliximab to biosimilar infliximab compared with maintained treatment with innovator infliximab in patients with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease and chronic plaque psoriasis



Acknowledgements

This trial was supported by a direct grant from the Norwegian government, by the Ministry of Health and Care Services.

Study coordinators: Kristin K Jørgensen, Guro Løvik Goll, Merete Lorentzen Statistician: Inge C Olsen Project group: Jørgen Jahnsen, Cato Mørk, Nils Bolstad, Espen A Haavardsholm, Knut EA Lundin, Ingrid P Berset, Bjørg TS Fevang, Jon Florholmen, Synøve Kalstad, Nils J Mørk, Kristin Ryggen, Kåre S Tveit, Sigrun K Sæther. Patient representatives: Bjørn Gulbrandsen, Jon Hagfors, Kenneth Waksvik

Investigators, nurses and participating patients at each study site

Data monitoring: Martha Colban, Nina Flatner, Trond Smedsrud, Bjørn Solvang, Inger Hilde Zahl, Cecilie Moe, Trude Langeng and the Norwegian Clinical Research Infrastructure Network (NorCRIN)

Study objectives

Primary:

 To assess if CT-P13 is non-inferior to innovator infliximab (INX) with regard to disease worsening in patients who have been on stable INX treatment for at least 6 months

Secondary:

- To assess the safety and immunogenicity of CT-P13 compared to INX in patients who have been on stable INX treatment for at least 6 months
- To compare the efficacy of CT-P13 to INX in patients who have been on stable INX treatment for at least 6 months applying generic and disease-specific outcome measures



Main Inclusion Criteria

- A clinical diagnosis of either rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease or chronic plaque psoriasis
- Male or non-pregnant, non-nursing female
- >18 years of age at screening
- Stable treatment with innovator infliximab (Remicade[®]) during the last 6 months
- Subject capable of understanding and signing an informed consent form
- Provision of written informed consent



Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial



Kristin K Jørgensen*, Inge C Olsen*, Guro L Goll*, Merete Lorentzen*, Nils Bolstad, Espen A Haavardsholm, Knut E A Lundin, Cato Mørk†, Jørgen Jahnsen†, Tore K Kvien†, on behalf of the NOR-SWITCH study group

Published Online May 11, 2017 http://dx.doi.org/10.1016/ S0140-6736(17)30068-5

THE LANCET


"NOR-SWITCH is, to our knowledge, the first randomised study to show that switching from an originator to a biosimilar TNF inhibitor is not inferior to continued treatment with the originator drug, according to a prespecified non-inferiority margin of 15%."

See Articles page 2304

Comment Renewed push to strengthen vector control globally	Articles Long-term management of moderate-to-severe atopic dermatitis with dupilumab	Articles Switching from originator infliximab to biosimilar CT-P13 compared with	Articles Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to	Series Targeted treatments for rheumatoid arthritis See pages 2328 and 2338
See page 2270	and concomitant topical corticosteroids See page 2287	maintained treatment with originator infliximab See page 2304	tumour necrosis factor inhibitors See page 2317	
00 Registered as a newspa nded 1823 · Published week	aper - ISSN 0140-6736			

NOR-SWITCH Study Design

- Exploring switching for non-medical reasons
- Primary endpoint: Effectiveness (disease worsening)



A randomized, double-blind, parallel-group study to evaluate the safety and efficacy of switching from innovator infliximab to biosimilar infliximab compared with continued treatment with innovator infliximab in patients with rheumatoid arthritis, spondylarthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease and chronic plaque psoriasis

Assumption : 30% Open Label worsening in 52 Follow-up weeks Non-inferiority margin:15%




Table 1: The numbers in the cells represent the total number of patients needed in total. All calculations are based on a power of 80% and alpha 2.5%


Non- inferiority Margin	10% disease worsening at 52 w	20% disease worsening at 52 w	30% disease worsening at 52 w
10%	248	504	660
15 %	126	224	294
20 %	72	126	166

Table 2: The numbers in the cells represent the total number of patients needed in total. All calculations are based on a power of 90% and alpha 2.5%.

Non- inferiority Margin	10% disease worsening at 52 w	20% disease worsening at 52 w	30% disease worsening at 52w
10%	380	674	884
15 %	170	300	394
20 %	96	170	222

Diagnosis distribution







Primary endpoint

	INX	CT-P13	Rate difference
	(n= 202)	(n=206)	(95% CI)
Disease worsening*	53 (26.2%)	61 (29.6%)	-4.4 (-12.7 — 3.9)

* UC: increase in p-Mayo score of ≥ 3 points and a p-Mayo score of ≥ 5 points, CD: increase in HBI of ≥ 4 points and a HBI score of ≥7 points RA/PsA: increase in DAS28 of ≥ 1.2 from randomization and a DAS score of ≥
3.2 AS/SpA: increase in ASDAS of ≥1.1 and ASDAS of ≥ 2.1


Psoriasis: increase in PASI of \geq 3 points from randomization and a minimum PASI score of \geq 5

If a patient does not fulfill the formal definition, but experiences a clinically significant worsening according to both the investigator and patient and which leads to a major change in treatment this should be considered as a disease worsening but recorded separately in the CRF



Disease Worsening

INX	CT-P13	
n=202	n=206	Risk difference (95% CI)






Remission

	INX	CT-P13
	n=202	n=206 Rate difference (95% CI)
Diagnosis		
Crohn's disease	46 (69.7%)	41 (65·1%) 5·6% (-11·0 to 22·2%)
Ulcerative colitis	29 (87.9%)	39 (92·9%) -5·9% (-21·7 to 9·9%)
Spondyloarthritis	10 (23.3%)	7 (16·7%) 7·2% (-11·2 to 25·5%)
Rheumatoid arthritis	17 (56-7%)	19 (63·3%) -9·8% (-33·5 to 13·9%)
Psoriatric arthritis	6 (46·2%)	6 (46·2%) -1·8% (-39·9 to 36·3%)
Psoriasis	15 (88-2%)	14 (87·5%) 0·7% (-21·3 to 22·8%)
Overall	123 (60.9%)	126 (61·2%) 0·6% (-7·5 to 8·8%)
		-50 -40 -30 -20 -10 0 10 20 30 40 50 Favours CT-P13 % Favours INX



Global Assessment of Disease Activity





Patient


Physician




Disease Activity











HBI


p-Mayo score

ASDAS









CDAI




PASI



CRP and Calprotectin








CRP

Calprotectin



Drug Trough Levels






Anti-drug Antibodies (ADAb)

	INX (n= 241)	CT-P13 (n=240)
ADAb observed at any time point	26 (10.8%)	30 (12.5%)
Incidence of ADAb	17 (7.1%)	19 (7.9%)



Adverse events – safety population

Overview *	INX (n=241)	CT-P13 (n=240)
SUSAR	0	0
Serious adverse events (SAE)	[32] 24 (10·0%)	[27] 21 (8·8%)
Adverse events (AE)	[422] 168 (69·7%)	[401] 164 (68·3%)
Adverse event leading to study drug discontinuation	[18] 9 (3·7%)	[9] 8 (3·3%)






Interpretation

- The NOR-SWITCH trial demonstrated that switch from INX to CT-P13 was not inferior to continued treatment with INX
- The results support switching from INX to CT-P13 for non-medical reasons




NOR-SWITCH Study Design

- Exploring switching for non-medical reasons
- Primary endpoint: Effectiveness (disease worsening)



A randomized, double-blind, parallel-group study to evaluate the safety and efficacy of switching from innovator infliximab to biosimilar infliximab compared with continued treatment with innovator infliximab in patients with rheumatoid arthritis, spondylarthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease and chronic plaque psoriasis Assumption : 30% Open Label worsening in 52 Follow-up weeks Non-inferiority margin:15%






Nor-Switch extension: disease worsening

Diagnosis	Maintenance	Switch	Risk difference (95% CI)					
Crohn's disease	13/63 (20.6%)	8/61 (13.1%)	7.9% (-5.2 to 21)		2	-	-	<i>→</i>
Ulcerative colitis	6/39 (15.4%)	1/35 (2.9%)	12.4% (-0.1 to 25)			-	-	\rightarrow
Spondyloarthritis	3/38 (7.9%)	2/28 (7.1%)	0.6% (-12.2 to 13.5)		-			
Rheumatoid arthritis	9/26 (34.6%)	6/27 (22.2%)	10.5% (-13.6 to 34.6)				-	<i>→</i>
Psoriatic arthritis	1/8 (12.5%)	3/9 (33.3%)	-20.8% (-59.1 to 17.6)	-				-
Psoriasis	0/16 (0%)	0/13 (0%)	0% (-20.6,24.7)	-		-	ales.	+
Overall	32/190 (16.8%)	20/173 (11.6%)	5.9% (-1.1 to 12.9)			V		
				L	-		-	_
				-20	-10	0	10	20

Maintenance group: CT-P13 throughout study period Switch group: INX main study period, switched to CT-P13



Anti-drug Antibodies



*neutralising antibodies, measured only in patients with drug trough level ≤ 5 mg/L



Interpretation

- The NOR-SWITCH extension trial confirms results from main trial:
 - a switch from INX to CT-P13 did not lead to an increased rate of disease worsening, adverse events or immunogenicity concerns in overall study population





Conclusions


- Most data support that switching/transitioning from originator bDMARD to bsDMARD is safe
- Cost-saving is the major (only?) motivation combined with better access to good therapies for more people
- Nocebo-effect may be an issue and more data are needed on how information may improve acceptability and drug retention

Biosimilar uptake in Norway









The future and research agenda

- Switching from biosimilar back to originator?
- Multiple switches between biosimilars
- Interchangeability versus automatic substitution
- Nocebo effect and communication strategies

Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases

Jonathan Kay,¹ Monika M Schoels,² Thomas Dörner,³ Paul Emery,⁴ Tore K Kvien,⁵ Josef S Smolen,^{2,6} Ferdinand C Breedveld,⁷ on behalf of the Task Force on the Use of Biosimilars to Treat Rheumatological Diseases

To cite: Kay J, Schoels MM, Dörner T, et al. Ann Rheum Dis Published Online First: [please include Day Month Year]. doi:10.1136/ annrheumdis-2017-211937

		Agreement* (%)	Level of evidence†	Grade of recommendation
Over	arching principles			
A.	Treatment of rheumatic diseases is based on a shared decision-making process between patients and their rheumatologists.	100	5	D
B.	The contextual aspects of the healthcare system should be taken into consideration when treatment decisions are made.	100	5	D
C.	A biosimilar, as approved by authorities in a highly regulated area, is neither better nor worse in efficacy and not inferior in safety to its bio-originator.	88	5	D
D.	Patients and healthcare providers should be informed about the nature of biosimilars, their approval process, and their safety and efficacy.	96	5	D
E.	Harmonised methods should be established to obtain reliable pharmacovigilance data, including traceability, about both biosimilars and bio-originators.	100	5	D
Cons	ensus recommendations			
1.	The availability of biosimilars must significantly lower the cost of treating an individual patient and increase access to optimal therapy for all patients with rheumatic diseases.	100	5	D
2.	Approved biosimilars can be used to treat appropriate patients in the same way as their bio-originators.	100	1b	А
3.	As no clinically significant differences in immunogenicity between biosimilars and their bio-originators have been detected, antidrug antibodies to biosimilars need not be measured in clinical practice.	100	2b	В
4.	Relevant preclinical and phase I data on a biosimilar should be available when phase III data are published.	100	5	D
5.	Since the biosimilar is equivalent to the bio-originator in its physicochemical, functional and pharmacokinetic properties, confirmation of efficacy and safety in a single indication is sufficient for extrapolation to other diseases for which the bio-originator has been approved.	100	5	D
6.	Currently available evidence indicates that a single switch from a bio-originator to one of its biosimilars is safe and effective; there is no scientific rationale to expect that switching among biosimilars of the same bio-originator would result in a different clinical outcome but patient perspectives must be considered.	96	1b	A
7.	Multiple switching between biosimilars and their bio-originators or other biosimilars should be assessed in registries.	100	5	D
8.	No switch to or among biosimilars should be initiated without the prior awareness of the patient and the treating healthcare provider.	91	5	D

(1, 0) for (1, 0)

Table 4. Overseline estadables (A. E) and see

†1a: systematic review of randomised clinical trials (RCTs); 1b: individual RCT; 2a: systematic review of cohort studies; 2b: individual cohort study (including low-quality RCT; eg, <80% follow-up); 3a: systematic review of case–control studies; 3b: individual case–control study; 4: case-series (and poor quality cohort and case–control studies); 5: expert opinion without explicit critical appraisal, or based on physiology, bench research or 'first principles'.</p>

\$A: based on consistent level 1 evidence; B: based on consistent level 2 or 3 evidence or extrapolations from level 1 evidence; C: based on level 4 evidence or extrapolations from level 2 or 3 evidence; D: based on level 5 evidence or on troublingly inconsistent or inconclusive studies of any level.